Drug intelligence / Profile preview

haloxazolam

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Haloxazolam is a benzodiazepine derivative and small molecule drug primarily marketed in Japan under the brand name Somelin. It is indicated for the treatment of insomnia and exhibits sedative, hypnotic, and anxiolytic properties similar to other benzodiazepines such as triazolam, temazepam, and flunitrazepam. Its mechanism of action involves positive allosteric modulation of the GABA A receptor, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. Haloxazolam is classified as a Schedule IV controlled substance due to its low potential for abuse relative to other substances[1][3][4][5]. The drug undergoes hepatic metabolism and renal excretion.

Brand names: Somelin
Other names: Haloxazolamum

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on haloxazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloxazolam.

Explore the full profile